论文部分内容阅读
由于蒽环类药物显著的抗肿瘤作用和广泛的临床应用,其临床应用的安全性越来越受到重视。该类药物的心脏毒性表现为剂量限制性的特点。目前唯一获批的蒽环类药物心脏毒性保护剂只有右丙亚胺,其心脏保护作用已经得到了广泛认可,并被美国临床肿瘤实践指南及其他多种国内外指南推荐应用于蒽环类药物心脏毒性的预防和治疗。有关右丙亚胺的临床应用策略,目前仍存在一定争议。本文探讨了右丙亚胺对蒽环类药物抗肿瘤效价的影响、右丙亚胺用药时机的选择、右丙亚胺临床应用的安全性以及正在研究中的可能具有心脏保护功能的药物。
Due to the significant antitumor effect and broad clinical application of anthracyclines, the safety of its clinical application has drawn more and more attention. Cardiac toxicity of these drugs showed dose-limiting characteristics. Currently the only anthracycline cardiotoxic protective agent approved only dexrazoxane, its cardioprotective effect has been widely recognized by the United States and other clinical guidelines for clinical practice guidelines and many other guidelines recommended domestic and international anthracycline drugs Prevention and treatment of cardiotoxicity. There are still some controversies about the clinical application strategy of dexrazoxane. This article explored the effect of dexrazoxane on the antitumor potency of anthracyclines, the timing of dexrazoxane dosing, the safety of dexrazoxane in clinical use, and the potentially protective cardioprotective agents under study.